Bocchetta A, Cherchi A, Loviselli A, Mossa P, Velluzzi F, Derai R, Del Zompo M
Department of Neurosciences B.B. Brodie, University of Cagliari, Italy.
Acta Psychiatr Scand. 1996 Jul;94(1):45-8. doi: 10.1111/j.1600-0447.1996.tb09823.x.
A cohort of patients at various stages of lithium treatment was followed up for 6 years in order to evaluate the course of thyroid abnormalities. Ultrasonography confirmed that lithium can increase thyroid size, especially in cigarette smokers, and that it can affect the texture of the gland. However, the incidence of clinical hypothyroidism or specific thyroid autoimmunity does not exceed that found in the general population. Repeated determinations of thyrotrophin (TSH) concentrations can prevent clinically relevant consequences. Addition of carbamazepine to lithium can counteract lithium-induced subclinical hypothyroidism, possibly improving prophylactic efficacy in recurrent affective disorders.
对一组处于锂治疗不同阶段的患者进行了6年的随访，以评估甲状腺异常的病程。超声检查证实，锂可增大甲状腺大小，尤其是在吸烟者中，并且会影响甲状腺的质地。然而，临床甲状腺功能减退症或特定甲状腺自身免疫的发生率并未超过普通人群。重复测定促甲状腺激素（TSH）浓度可预防临床相关后果。在锂治疗中加用卡马西平可抵消锂诱导的亚临床甲状腺功能减退，可能会提高对复发性情感障碍的预防效果。
